Cyclacel Pharmaceuticals, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Bio Green Med Solution, Inc. announced a quarterly cash dividend of $0.15 per share for its 6% Convertible Exchangeable Preferred Stock.
Bio Green Med Solution, Inc. announced the closing of a $794,403 private placement of common stock to foreign accredited investors.
Bio Green Med Solution, Inc. has entered into a definitive agreement to acquire Future NRG Sdn. Bhd. in an all-stock transaction to create a diversified environmental and safety services platform.
Bio Green Med Solution announced first quarter 2026 financial results, highlighting progress in its fire safety business and a significant reduction in general and administrative expenses.
Bio Green Med Solution, Inc. announced its Board of Directors has declared a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Preferred Stock.
Bio Green Med Solution, Inc. announced its fourth quarter and full year 2025 financial results, highlighting a strategic pivot to fire safety and distribution activities.
Bio Green Med Solution, Inc. announced the delisting of its 6% Convertible Exchangeable Preferred Stock from The Nasdaq Capital Market due to non-compliance with the minimum Market Value of Publicly Held Shares requirement.
Bio Green Med Solution, Inc. announced a quarterly cash dividend of $0.15 per share for its 6% Convertible Exchangeable Preferred Stock.
Bio Green Med Solution, Inc. announced its third quarter 2025 financial results and a significant strategic shift from biopharmaceuticals to fire safety protection and distribution activities.
Bio Green Med Solution, Inc. exchanged existing warrants held by accredited investors for 1,402,605 shares of its common stock.
Bio Green Med Solution, Inc. announced a quarterly cash dividend of $0.15 per share for its 6% Convertible Exchangeable Preferred Stock.
Bio Green Med Solution, Inc. has sold its Plogosertib assets, a PLK1 inhibitor for advanced cancers, to Tethra Biosciences Inc. for an initial $300,000 and a potential $170,000 milestone payment.
Bio Green Med Solution, Inc. announced the resignation of an independent director and the appointment of Ms. Soon Ping (Zara) Pappas to its Board, maintaining Nasdaq independence requirements.
Bio Green Med Solution, Inc. filed an amended 8-K to correct its corporate logo on the cover page, aligning it with its new name and ticker symbols.
Bio Green Med Solution, Inc. received a Nasdaq notice for its preferred stock failing to meet the minimum $1 million market value requirement, with a compliance deadline of March 10, 2026.
Bio Green Med Solution, Inc. has completed the acquisition of Fitters Sdn. Bhd., diversifying its business into fire protection and safety equipment alongside its existing biopharmaceutical interests.
Cyclacel Pharmaceuticals shareholders approved key proposals including a name change to Bio Green Med Solution, Inc. and significant stock issuances.
Cyclacel Pharmaceuticals, Inc. has entered into a Warrant Exchange Agreement with accredited investors to exchange existing Series C common stock purchase warrants for new common stock.
Cyclacel Pharmaceuticals, Inc. has amended its Series A, B, and C common stock purchase warrants, removing the previous ownership limitation to allow for unrestricted exercise and voting.
Cyclacel Pharmaceuticals dismissed its independent auditor, Bush & Associates, and appointed SFAI Malaysia PLT after Bush raised substantial doubt about the company's ability to continue as a going concern.
Cyclacel Pharmaceuticals announced its second quarter 2025 financial results, highlighting reduced net loss, a significant share exchange agreement, and a reverse stock split to meet Nasdaq requirements.
Cyclacel Pharmaceuticals reported a significantly reduced net loss in Q1 2025 due to a one-time gain from subsidiary deconsolidation, while auditors raised substantial doubt about its ability to continue as a going concern.
Cyclacel Pharmaceuticals, Inc. has amended its Series F Convertible Preferred Stock Certificate of Designation, removing the ownership limitation that previously restricted conversion and voting rights.
Cyclacel Pharmaceuticals, Inc. commented on recent stock price volatility, stating no material adverse changes to its operations or financial condition, while confirming a proposed transaction with FITTERS Diversified Berhad.
8-K: Cyclacel Amends Merger Agreement with Fitters, Adds $1 Million Cash Payment and Extends Deadline
Cyclacel Pharmaceuticals, Inc. has amended its share exchange agreement with FITTERS Diversified Berhad, adding a $1 million cash payment to Fitters Parent due to a decline in Cyclacel's valuation and extending the closing deadline to September 30, 2025.
Cyclacel Pharmaceuticals, Inc. announced a 1-for-15 reverse stock split, effective July 7, 2025, primarily to meet Nasdaq Capital Market's bid price requirements.
Cyclacel Pharmaceuticals, Inc. shareholders overwhelmingly approved the re-election of five directors, an amendment to the 2018 Equity Incentive Plan, and executive compensation at their 2025 Annual Meeting.
Cyclacel Pharmaceuticals, a biopharmaceutical company, announced a $3 million private placement offering of convertible Series F Preferred Stock and associated warrants to fund general corporate and operating purposes, extending its cash runway into the third quarter of 2025.
Cyclacel Pharmaceuticals, Inc. announced a quarterly cash dividend of $0.15 per share for its 6% Convertible Exchangeable Preferred Stock, payable on August 1, 2025.
Cyclacel Pharmaceuticals, Inc. announced it has successfully regained compliance with Nasdaq's minimum bid price requirement, resolving a previously disclosed listing deficiency and ensuring its continued listing.